Ethical considerations for the clinical oncologist in an era of oncology drug shortages

Oncologist

Volumn 19, Issue 2, 2014, Pages 186-192

  Jagsi, Reshma ^a   Spence, Rebecca ^b   Kimryn Rathmell, W ^c   Bradbury, Angela ^d   Peppercorn, Jeffrey ^e   Grubbs, Stephen ^f   Moy, Beverly ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DUKE UNIVERSITY   (United States)

^f Medical Oncology Hematology Consultants   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug; Ethics; Oncology; Policy; Recommendations; Shortage

Indexed keywords

ADVISORY COMMITTEE; ARTICLE; CONCEPTUAL FRAMEWORK; DRUG DEFICIENCY; DRUG SHORTAGE; ETHICS; HUMAN; MEDICAL LITERATURE; ONCOLOGIST; PRIORITY JOURNAL; UNITED STATES; CASE REPORT; CHILD; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE ORGANIZATION; MIDDLE AGED; NEOPLASMS; ONCOLOGY; PHYSICIAN; PROCEDURES; SUPPLY AND DISTRIBUTION;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CHILD; DRUG COSTS; FEMALE; HEALTH CARE RATIONING; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; PHYSICIANS; UNITED STATES;

EID: 84894067849     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0301     Document Type: Article

References (40)

1. Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer-The example of mechlorethamine. N Engl J Med 2012; 367:2461-2463.
2. Valgus J, Singer EA, Berry SR et al. Ethical challenges: Managing oncology drug shortages. J Oncol Pract 2013;9:e21-e23.
3. Blume E. Investigators seek to increase taxol supply. J Natl Cancer Inst 1989;81:1122-1123.
4. Landis N. Provisional observations on drug product shortages: Effects, causes, and potential solutions. AmJHealthSystPharm2002;59:2173-2182. Available at http://www.ashp.org/s_ashp/docs/files/ DShort_11b-SF-Witmer.pdf.
5. Park A. Inside America's drug shortage. Time, March 2012. Available at http://healthland.time. com/2012/03/19/where-have-all-our-drugs-gone/.
6. U.S. Food and Drug Administration, Center for Drugs and Evaluation Research Drug Shortage Program. Frequently asked questions about drug shortages. Available at http://www.fda.gov/ Drugs/DrugSafety/DrugShortages/ucm050796. htm#q1.
7. Fox ER, Birt A, James KB et al; ASHP Expert Panel on Drug Product Shortages. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm 2009;66: 1399-1406.
8. Hoffman S. The drugs stop here: A public health framework to address the drug shortage crisis. Food Drug Law J 2012;67:1-22.
9. Kaakeh R, Sweet BV, Reilly C et al. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm 2011;68:1811-1819.
10. McBride A, Holle LM, Westendorf C et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm 2013;70:609-617.
11. Haninger K, Jessup A, Koehler K. Economic analysis of the causes of drug shortages (ASPE issue brief). Washington, DC: United States Department of Health andHuman Services,2011. Available at http:// www.aspe.hhs.gov/sp/reports/2011/drugshortages/ ib.shtml.
12. Chabner BA. Drug shortages-a critical challenge for the generic-drug market. N Engl J Med 2011;365:2147-2149.
13. Jacobson M, Alpert A, Duarte F. Prescription drug shortages: Reconsidering the role of Medicare payment policies. Available at http://healthaffairs. org/blog/2012/05/29/prescription-drug-shortagesreconsidering-the-role-of-medicare-payment-policies.
14. Office of the Press Secretary. We can't wait: Obama Administration takes action to reduce prescription drug shortages, fight price gouging [press release]. Washington, DC: White House, 2011. Available at http://www.whitehouse.gov/the-press-office/ 2011/10/31/we-can-t-wait-obama-administrationtakes-action-reduce-prescription-drug.
15. U.S. Food and Drug Administration. FDA acts to bolster supply of critically needed cancer drugs [press release], 02/2012 update. Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm292658.htm.
16. U.S. Food and Drug Administration. FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage. Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm337872.htm.
17. U.S. Food and Drug Administration. The Food and Drug Administration Safety and Innovation Act (FDASIA), S. 3187, 2012. Available at http://www. gpo.gov/fdsys/pkg/BILLS-112s3187pcs/pdf/BILLS-112s3187pcs.pdf.
18. Callahan D. Rationing: theory, politics, and passions. Hastings Cent Rep 2011;41:23-27.
19. Aaron HJ, Schwartz WB. The Painful Prescription: Rationing Hospital Care. Washington, DC: Brookings Institution, 1984.
20. Aaron HJ, Schwartz WB. Can We Say NO? The Challenge of Rationing Health Care. Washington, DC: Brookings Institution, 2005.
21. Ubel PA. Pricing Life: Why It's Time for Health Care Rationing. Cambridge, MA: MIT Press, 2000.
22. Boulis A, Goold S, Ubel PA. Responding to the immunoglobulin shortage: A case study. J Health Polit Policy Law 2002;27:977-999.
23. Health Resources and Services Administration. Organ distribution: Allocation of deceased kidneys, 9/12 update. Available at http://optn.transplant.hrsa. gov/PoliciesandBylaws2/policies/pdfs/policy_7.pdf.
24. Scribner BH. Lasker ClinicalMedicine Research Award. Medical dilemmas: The old is new. Nat Med 2002;8:1066-1067.
25. Strosberg M, Wiener J, Baker R et al., eds. RationingAmerica'sMedicalCare:TheOregonPlanand Beyond. Washington, DC: Brookings Institution, 1992.
26. Jagsi R, DeLaney TF, Donelan K et al. Real-time rationing of scarce resources: The Northeast Proton Therapy Center experience. J Clin Oncol 2004;22: 2246-2250.
27. Calabresi G, Bobbitt P. Tragic Choices. New York, NY:W.W. Norton, 1978.
28. Bloche MG. Clinical loyalties and the social purposes of medicine. JAMA 1999;281:268-274.
29. Ubel PA, Arnold RM. The unbearable rightness of bedside rationing. Physician duties in a climate of cost containment. Arch Intern Med 1995;155: 1837-1842.
30. Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff (Millwood) 1998;17:50-64.
31. Rosoff PM. Unpredictable drug shortages: An ethical framework for short-term rationing in hospitals. Am J Bioeth 2012;12:1-9.
32. Rosoff PM, Patel KR, Scates A et al. Coping with critical drug shortages: An ethical approach for allocating scarce resources in hospitals. Arch Intern Med 2012;172:1494-1499.
33. Burda ML. Beyond the framework. AmJ Bioeth 2012;12:11-13.
34. Goodman A. The tensions and challenges of unpredictable drug shortages. AmJ Bioeth 2012;12: 20-22.
35. Bamford R, Brewer CD, Bucknell B et al. A paradoxical ethical framework for unpredictable drug shortages. Am J Bioeth 2012;12: 16-18.
36. Caro JJ, Coleman CN, Knebel A et al. Unaltered ethical standardsfor individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event. J Clin Ethics 2011; 22:33-41.
37. Thompson AK, Faith K, Gibson JL et al. Pandemic influenza preparedness:Anethical framework to guide decision-making. BMC Med Ethics 2006;7:E12.
38. Gibson JL, Bean S, Chidwick P et al. Ethical framework for resource allocation during a drug supply shortage. Healthc Q 2012;15:26-35.
39. Peppercorn J, Armstrong A, Zaas DW et al. Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer. Urol Oncol 2013; 31:1079-1084.
40. Link MP, Hagerty K, Kantarjian HM. Chemotherapydrugshortages in the United States: Genesis and potential solutions. J Clin Oncol 2012;30: 692-694.